Status:
NOT_YET_RECRUITING
Glucose Disposal Rate as a Metric for Detection of Metabolic Associated Fatty Liver
Lead Sponsor:
Assiut University
Conditions:
MAFLD
Eligibility:
All Genders
18-65 years
Brief Summary
A 12-month prospective observational cohort study assessing eGDR's utility in diagnosing MAFLD (via FibroScan® CAP ≥248 dB/m) and correlating it with steatosis/fibrosis severity. Secondary aims compar...
Detailed Description
Primary Aim Determine eGDR's diagnostic accuracy for MAFLD using FibroScan® (CAP ≥248 dB/m) as the gold standard. Secondary Aims Correlate eGDR with MAFLD severity (steatosis via CAP, fibrosis via ...
Eligibility Criteria
Inclusion
- Age 18-65 years.
- Suspected/confirmed MS per IDF criteria:
- Central obesity (waist circumference ≥94 cm \[men\]/≥80 cm \[women\]) plus ≥2 of: Triglycerides ≥150 mg/dL.
- HDL \<40 mg/dL (men)/\<50 mg/dL (women). Blood pressure ≥130/85 mmHg or antihypertensive treatment. Fasting glucose ≥100 mg/dL or diabetes diagnosis.
Exclusion
- Other liver diseases (viral/autoimmune hepatitis).
- Alcohol intake \>20 g/day (men) or \>10 g/day (women).
- Pregnancy, malignancy, advanced cirrhosis.
- Medications affecting metabolism (e.g., steroids)
Key Trial Info
Start Date :
July 30 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06923215
Start Date
July 30 2025
End Date
December 30 2026
Last Update
April 11 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.